Edesa Biotech, Inc. (EDSA)
$2.85-3.06%Close
SELLCRISIS · day 38
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $27M
- Beta
- 1.06
- P/E (TTM)
- -1.68
- Short % float
- 2.65%
- Days to cover
- 4.8
- SI change
- -7.0%
- 1W
- -23.39%
- 1M
- -31.16%
- vs SPY 1W
- -23.25%
- vs SPY 1M
- -33.67%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 7
- VALUE
- 5
- GROWTH
- 39
- GARP
- 0
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-74.5%
REV YoY-
ROE-124.2%
EPS YoY-
ROA-110.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.68
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B2.91
P/FCF-
EV/EBITDA-1.20
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO2.76
ND/EBITDA-
BETA1.06
Company news
FAQ
- What is LOPJLB’s current signal on EDSA?
- LOPJLB’s latest quantitative signal on Edesa Biotech, Inc. (EDSA) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is EDSA in?
- Edesa Biotech, Inc. (EDSA) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Edesa Biotech, Inc. (EDSA) do?
- Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, a…